Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kévin Chemello

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Atherosclerosis|May 23, 2022
Recent advances in demystifying the metabolism of lipoprotein(a)Kévin Chemello, Dick C Chan, Gilles Lambert, et al.
Journal of Lipid Research|August 16, 2023
PCSK9 and the nervous system: a no-brainer?Ali K Jaafar, Romuald Techer, Kévin Chemello, et al.
Current Atherosclerosis Reports|March 31, 2022
Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E IsoformsKévin Chemello, Dirk J Blom, A David Marais, et al.
Journal of Lipid Research|March 6, 2021
Lipoprotein metabolism in familial hypercholesterolemiaKévin Chemello, Javier García-Nafría, Antonio Gallo, et al.
Journal of the American Heart Association|April 16, 2025
Apolipoprotein E Plasma Concentrations Are Predictive of Recurrent Strokes: Insights From the SPARCL TrialKévin Chemello, Alexis F Guedon, Romuald Techer, et al.
JACC. Advances|June 28, 2024
Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors: Insights From the SPARCL TrialKévin Chemello, Antonio Gallo, Alexis F Guedon, et al.
JCI Insight|May 8, 2025
PCSK9 deficiency promotes the development of peripheral neuropathyAli K Jaafar, Aurélie Paulo-Ramos, Guillaume Rastoldo, et al.
Cardiovascular Research|July 27, 2021
The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitorsValentin Blanchard, Kévin Chemello, Tim Hollstein, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 30, 2017
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of EvolocumabAurélie Thedrez, Dirk J Blom, Stéphane Ramin-Mangata, et al.
International Journal of Molecular Sciences|March 11, 2023
Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort StudyFloran Begue, Kévin Chemello, Bryan Veeren, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Atherosclerosis|May 23, 2022
Recent advances in demystifying the metabolism of lipoprotein(a)Kévin Chemello, Dick C Chan, Gilles Lambert, et al.
Journal of Lipid Research|August 16, 2023
PCSK9 and the nervous system: a no-brainer?Ali K Jaafar, Romuald Techer, Kévin Chemello, et al.
Current Atherosclerosis Reports|March 31, 2022
Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E IsoformsKévin Chemello, Dirk J Blom, A David Marais, et al.
Journal of Lipid Research|March 6, 2021
Lipoprotein metabolism in familial hypercholesterolemiaKévin Chemello, Javier García-Nafría, Antonio Gallo, et al.
Journal of the American Heart Association|April 16, 2025
Apolipoprotein E Plasma Concentrations Are Predictive of Recurrent Strokes: Insights From the SPARCL TrialKévin Chemello, Alexis F Guedon, Romuald Techer, et al.
JACC. Advances|June 28, 2024
Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors: Insights From the SPARCL TrialKévin Chemello, Antonio Gallo, Alexis F Guedon, et al.
JCI Insight|May 8, 2025
PCSK9 deficiency promotes the development of peripheral neuropathyAli K Jaafar, Aurélie Paulo-Ramos, Guillaume Rastoldo, et al.
Cardiovascular Research|July 27, 2021
The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitorsValentin Blanchard, Kévin Chemello, Tim Hollstein, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 30, 2017
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of EvolocumabAurélie Thedrez, Dirk J Blom, Stéphane Ramin-Mangata, et al.
International Journal of Molecular Sciences|March 11, 2023
Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort StudyFloran Begue, Kévin Chemello, Bryan Veeren, et al.
Pageof 2